Cytokinetics presents new data at CMR 2024 from FOREST-HCM

Cytokinetics announced new data at CMR 2024 demonstrating favorable effects on cardiac structure, function and fibrosis related to treatment with aficamten in FOREST-HCM, the open label extension clinical trial of aficamten in patients with hypertrophic cardiomyopathy, HCM. New data presented from the cardiac magnetic resonance sub-study in FOREST-HCM show that treatment with aficamten for 48 weeks resulted in favorable cardiac structural remodeling, improvements in cardiac function, and stabilization of myocardial fibrosis. At the time of this analysis, 16 patients in FOREST-HCM had completed a CMR at baseline and at Week 48. Baseline characteristics of the CMR cohort were comparable to the overall patient population in FOREST-HCM. In this trial, treatment with aficamten for 48 weeks resulted in statistically significant improvements in measures of cardiac structure and function including left ventricular mass index, maximum left ventricular septal wall thickness, left atrial volume, and mitral regurgitant volume and fraction. Additionally, treatment with aficamten stabilized interstitial and replacement myocardial fibrosis, with no increase in the fibrosis mass, as measured by absolute mass of late gadolinium enhancement.